Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

on, which
is a counter-reaction of the body potentially decreasing the efficacy of current drug therapy1. In contrast to small molecule inhibitors, which display large variations in serum drug levels throughout the day, the vaccine-induced anti-angiotensin II antibodies were found to decline with a half-life of about 4 months. This may lead to a practically continuous inhibition of angiotensin II for weeks, which may in part account for the minor reactive rise observed in plasma renin concentration, and to the potent effect of the vaccine in early morning hours, as is further explained in the quote of Dr. Müller below.

A further important finding of the study is the dependence of efficacy on both the dose of the vaccine and the levels of induced anti-angiotensin II antibodies. Two doses of the vaccine, 100 ?g and 300 ?g, were tested in the trial. The induced anti-angiotensin antibody levels were significantly higher at the 300 ?g than at the 100 ?g dose (p=0.0098). Accordingly, blood pressure reduction was much larger and only significant at the 300 ?g dose (p=0.0498). Efficacy was thus driven by a longlasting, although reversible antibody response. Dr. Philipp Müller, EVP Clinical Development at Cytos Biotechnology comments on the study results:

“These data highlight a very important new aspect of the vaccine CYT006-AngQb, namely its exceptionally good control of the early morning blood pressure. So far, inhibition of the reninangiotensin system has been studied clinically only with small molecule inhibitors, which all produce a daily pattern of peaks and troughs in drug levels. Here, a trough in drug levels coincides with a natural rise of the blood pressure in early morning hours. The combination of these effects may lead to insufficient control of the early morning blood pressure surge. An intervention with a different pharmacokinetic profile like the vaccine approach, which avoids daily peaks and troughs in drug l
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA ... that its common shares have been approved for listing and ... "EPIX". ESSA will begin trading on NASDAQ on ... the TSX Venture Exchange under the symbol "EPI". ... on the NASDAQ, each of the Company,s outstanding special warrants ...
(Date:7/2/2015)... , July 2, 2015 ... as ,Friendly Aedes aegypti , , reduced ... Brazil by 95%, well below ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS ... trial of Oxitec,s genetically engineered mosquitoes. The results showed ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... , May 7 Young Innovations, Inc. (Nasdaq: YDNT ) today ... per share, payable June 15, 2010 to all shareholders of record on ... , The Company also ... Mr. McKey joined the Company in November 2003 . He has assumed positions ...
... 7 Patients treated with the Zilver® ... two years, according to interim results from the ... late-breaking clinical trial at the Society for Cardiovascular ... The prospective, single-arm study is ongoing to evaluate ...
Cached Medicine Technology:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:7/3/2015)... ... 2015 , ... " Selfie on a Stick ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... documenting memories. , Almost every smartphone has an incredibly powerful camera built into it. ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening ... located in the Lone Star State. The premium frozen yogurt chain was listed as #22 ... opened June 19 in the Village at Bachman Lake, is located at:, 3701 W. Northwest ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Many Fourth ... in mind. That’s why Amica Insurance is sharing some tips to promote ... (CPSC), approximately 230 people go to the emergency room daily with fireworks-related injuries in ...
(Date:7/2/2015)... ... July 02, 2015 , ... Get ... the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have rapidly ... significant popularity has inspired four new, fun shades including: blue, lime, pink and ...
(Date:7/2/2015)... ... July 02, 2015 , ... When ... met for the late June Web-based session, the speakers discussed the importance of ... managing high-risk patients through coordinated care. , During the session, participants learned the ...
Breaking Medicine News(10 mins):Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4
... American men could be putting their health at risk ... results might threaten their masculinity. Because they prove their ... advice including HIV/AIDS testing goes against their notion of ... Department of Sociology at Yale University in the US, ...
... could lead to better therapies for severe forms of the ... the University of Texas Southwestern Medical Center have figured what ... when he or she has a severe staph infection. , ... infections but applicable to all people, could lead to ...
... 21 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) ... registration of MEVAC-A for the country of Thailand. The ... quarter of 2009. , This registration is required to ... in is Mellow Hope products such as MEVAC-A, MEVAC-DTaP, ...
... In the past decade the popularity of rock climbing has ... now enjoyed by more than 9 million people in the ... Center for Injury Research and Policy of the Research Institute ... of the sport has escalated, so have the number of ...
... , , NEW YORK, July 21 ... (SSW) is expanding its ranks with the hire of Ned Russell as EVP, ... a member of the agency,s Executive Team. , , ... sides of the marketing business. Most recently he was VP of Brand Marketing ...
... , MINNEAPOLIS, July 21 /PRNewswire-USNewswire / -- ... convened today in Minneapolis, MN to honor the 2009 ... the National Alliance for Caregiving and MetLife Foundation. The ... adults, rewarding innovation, effectiveness, and responsiveness to caregiver needs. ...
Cached Medicine News:Health News:'Go to the doctor? Only if I'm really sick ...' 2Health News:Immune System Gene Discovery Sheds Light on Staph Infections 2Health News:Hard To Treat Diseases (HTDS.PK) Thailand Registration 2Health News:First national study to examine rock climbing-related injuries 2Health News:Ned Russell Joins Saatchi & Saatchi Wellness 2Health News:The National Alliance for Caregiving and MetLife Foundation Honor Innovators Making a Difference in the Lives of Caregivers 2Health News:The National Alliance for Caregiving and MetLife Foundation Honor Innovators Making a Difference in the Lives of Caregivers 3Health News:The National Alliance for Caregiving and MetLife Foundation Honor Innovators Making a Difference in the Lives of Caregivers 4Health News:The National Alliance for Caregiving and MetLife Foundation Honor Innovators Making a Difference in the Lives of Caregivers 5
Its MicroPoint design and reference marks at 10, 50 and 100 L ensure accurate performance with a variety of multi-channel and single-channel pipettors....
... tip, the Finntip Wide is designed especially ... like genomic DNA. This tip eliminates the ... is excellent for use with extremely viscous ... diameter of the orifice is 1.1 mm ...
For plaque coring...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: